John M. Fahrenholz, MD, Vanderbilt University Medical Center, Nashville, Tennessee, discusses questions about nonadvanced systemic mastocytosis submitted by participants. Topics include triggers for mast cell activation, management strategies in the perioperative setting, diagnosis with consideration for hereditary alpha tryptasemia, and the optimal timing for the addition of avapritinib to the chosen therapies.
In an expert roundtable discussion, Matthew P. Giannetti, MD, Harvard Medical School, Brigham and Women’s Hospital Mastocytosis Center, Boston, Massachusetts; Lauren M. Madigan, MD, University of Utah, University…
Distinguishing indolent from advanced systemic mastocytosis is notoriously complex, even for seasoned clinicians. To simplify diagnosis, researchers developed a mathematical model using basic lab values, achieving 93% predictive…
In an interview conducted at the 2025 European Society for Blood and Marrow Transplantation Annual Meeting, Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, Guy’s and St…
Surgeon Commander VA Arun, INHS Asvini, Colaba, Mumbai, and Anil Handoo, MD, BLK-Max Superspeciality Hospital, Delhi, discuss systemic mastocytosis. They review classification and diagnostic criteria and the clinical…